Desogestrel/Ethinyl Estradiol

10月20日，欧加隆旗下复方口服避孕药欣妈富隆（通用名：去氧孕烯炔雌醇片）正式在阿里健康大药房线上首发。作为国内目前唯一获批避孕和月经周期调控双适应症的复方短效口服避孕药，欣妈富隆上线互联网医药平台后，将全面提升用药可及性，助力女性获得包括避孕、月经健康、生育力保护在内的健康呵护。 复方口服避孕药（combined oral contraceptives，COC）是目前全球范围广泛使用的高效避孕方法之一，是含有低剂量雌激素和孕激素（与女性体内天然的雌激素和孕激素相似）的复合甾体激素制剂。正确使用 COC 不仅可以有效避孕，还可以调节月经。 数据显示，目前超过1/3的育龄期女性受到月经紊乱的困扰。一项纳入15个省市100个社区9951名女性的妇科常见病的随机抽样调查，结果显示，未绝经的女性中，月经紊乱女性占34.5%。 北京协和医院妇产科田秦杰教授指出，规律月经是女性生殖健康非常重要的信号，与生殖内分泌系统息息相关。月经周期规律性为相邻两次月经周期天数相差不超过7天，经期长度为7天以内，经期出血量为5-80mL可以称之为月经正常。现代社会女性的观念依然传统，并不认为月经失调是一种疾病，由于大多数女性对月经的认知不准确，即使发生了异常月经，也意识不到其潜在的问题，不会选择到医院寻求医生的帮助。 “尤其对于刚初潮后的青春期女性，尚不能形成比较规律的月经周期。其实，临床有很多种方式可以管理月经异常，比如在医生的指导下，服用短效口服避孕药调节月经周期也是一种方式，来提高学习、生活和工作质量。”田秦杰说。 资料显示，欣妈富隆（去氧孕烯炔雌醇片）是全球首个获批20μg炔雌醇的复方口服短效避孕药COC，在全球有超过40年的使用经验，也是继妈富隆（去氧孕烯炔雌醇片）后又一款低剂量炔雌醇(EE)产品，为女性提供更丰富的生殖健康守护和赋权自我的力量。 2022年，欣妈富隆正式回归中国市场，并于2023年7月正式进入国内医院。双通道政策下，今年5月，欣妈富隆正式进驻零售药店，10月正式在医药电商平台开售，实现了院内院外的全渠道便捷可及。 据了解，此次欧加隆联合阿里健康线上首发欣妈富隆，将借助阿里健康遍及全国百城的专业药品仓配体系与互联网诊疗能力，为更多中国女性提供专业有效、正品优质的创新治疗方案与药品服务。关爱女性多样化的健康需求，为女性管理自身特有健康需求提供便利。 一审| 黄佳 二审| 李芳晨 三审| 李静芝

iStock, Mininyx Doodle The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials. Roivant has struck another deal to sell one of its “vants.” This time around, the dermatology focused Dermavant will head to Organon in a deal valued up to $1.2 billion. Organon will be the new owner of Vtama, a non-steroidal topical therapy for plaque psoriasis that was approved in 2022. The cream is also currently under FDA review for atopic dermatitis, with a decision expected before the end of the year. Jefferies analysts said Dermavant was considered the lesser of Roivant’s offerings. “Most considered Dermavant as value-destructive, so we’d argue it’s important from a sentiment perspective to off-load Dermavant,” they wrote in an investors note. The Organon deal, they added, clears the way for Roivant to spend more on pivotal programs for its autoimmune-focused company, Immunovant. The complex deal will see Organon pay out $175 million upfront, then a potential $75 million in milestones upon the AD approval and up to $950 million for certain commercial milestones. All told, the deal could reach $1.2 billion. Dermavant shareholders will also receive royalties on net sales. Organon CFO Matthew Walsh said in a statement that the deal was structured around specific milestone payments rather than an upfront lump sum, similar to how the pharma has done other recent deals. “This is consistent with our commitment to disciplined capital allocation as we look to continue to reduce our leverage, but also strategically add growth assets,” Walsh said. Organon is a women’s health–focused pharma company that spun out of Merck & Co. in 2021. CEO Kevin Ali said the acquisition of Dermavant fits in with the company’s mission to invest in treatments that affect women differently. In recent years, the company has primarily stuck to rights deals with major pharmas to bolster its offerings. Organon signed a deal with Eli Lilly for European rights to the pharma’s migraine meds Emgality and Rayvow for $50 million at the end of 2023. Other deals include the licensing of Daré Bioscience’s bacterial vaginosis gel Xaciato and Chinese rights to contraceptive pills Marvelon and Mercilon from Bayer, both in 2022. As for Roivant, the parent of Dermavant, the Matt Gline–led company has been the apple of Big Pharma’s eye for deal opportunities of late. Almost exactly a year ago, Roivant sold Telavant, which formed around a Pfizer-developed inflammatory bowel disease medicine, to Roche for a whopping $7.1 billion. Jefferies said the Organon deal removes $200 million in operating expenses from Roivant’s balance sheet, which the analysts said will likely be put into R&D at Immunovant, which is expecting to kick off several pivotal Phase III studies in the years to come. Immunovant is developing autoimmune disease therapies, including batoclimab for myasthenia gravis and thyroid eye disease. “Most investors were lukewarm on Dermavant given the modest revenue and slow launch trajectory while also incurring high OpEx i.e. cash burning and likely won’t flip profitable,” the firm wrote in a Wednesday note to clients. Jefferies was not too worried about Roivant’s cash position, as the company has a reported $5 billion on hand already, but the cost savings and flexibility it means for Immunovant are a nice bonus. As for whether Roivant will deal again—the company has 10 vants in its roster—Jefferies analysts said that while “multiple discussions are occurring,” Roivant executives have said they do not expect to make any business development announcements in the near term. “Timing ultimately comes down to pharma and not necessarily [Roivant] who logically wants to capitalize on the current BD environment,” Jefferies wrote.